Navigation Links
Study uses new stem cell therapy in patients up to 19 days after stroke
Date:7/14/2011

HOUSTON (July 14) The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston (UTHealth) in the country's first double-blind clinical trial studying the safety and efficacy of an innovative stem cell therapy that can be given up to 19 days after an ischemic stroke.

The Phase II study, cleared by the Federal Drug Administration, examines a regenerative therapy developed by Aldagen that uses a patient's own bone marrow stem cells. The therapy, called ALD-401, consists of stem cells that are identified using Aldagen's proprietary technology to isolate cells that express high levels of an enzyme that serve as a marker of stem cells.

Studies found that these cells enhance recovery after stroke in mice. The cells are administered into the carotid artery.

"This represents a new approach using stem cells for stroke," said Sean Savitz, M.D., senior investigator for the multi-center study and associate professor of neurology at the UTHealth Medical School. "A major question in the field of stem cell research is whether we can extend the time window for administering stem cells. A longer window increases the number of patients that might be helped."

Preclinical research, including research at UTHealth, has suggested that stem cells can promote the repair of the brain after an ischemic stroke, which is caused by a blood clot in the brain. Stroke is a leading cause of disability and the fourth-leading cause of death in the United States, according to 2008 statistics reported by the Centers for Disease Control and Prevention.

The Houston resident received either placebo or ALD-401 on June 8 at Memorial Hermann-Texas Medical Center after suffering a stroke May 23 while on a trip to California. Her stroke was caused by previously undiagnosed atrial fibrillation.

"We were waiting for our taxi at the hotel and I immediately couldn't talk and my husband said my face was drooping," said the 67-year-old cosmetics developer. "We were just three blocks from a major trauma center. I had an angel with me because if it had happened two hours later, I would have been on an airplane."

Once back in Houston, she was referred to Savitz' study by Erin Furr-Stimming, M.D., UTHealth assistant professor of neurology, who treats her for Parkinson's disease.

While she doesn't know whether or not she received the stem cells in the double-blind study, she didn't hesitate to join the trial.

"I did a lot of research on stem cells online. I was very excited when I heard about the trial. I wanted to participate in the research for me, if possible, and for other people behind me," she said.

Savitz and his research team are studying other stem cell therapies for acute stroke, and these must be administered within a few days of the stroke. One of those, a safety and efficacy trial using a patient's own bone marrow stem cells administered intravenously, is funded by the National Institutes of Health. UTHealth researchers in the Department of Pediatric Surgery also are studying the use of stem cells for pediatric traumatic brain injury.


'/>"/>

Contact: Deborah Lake
deborah.m.lake@uth.tmc.edu
University of Texas Health Science Center at Houston
Source:Eurekalert  

Related biology news :

1. Study challenges baby formula claim
2. Study explains why men are at higher risk for stomach cancer
3. First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool
4. Your mother was right: Study shows good posture makes you tougher
5. Researchers study pesticide pathways into the atmosphere
6. Scleroderma study identifies roadblocks to employment
7. Study: People at risk for panic buffered from stressor by high levels of physical activity
8. UCI study points to new means of overcoming antiviral resistance in influenza
9. Owl study expands understanding of human stereovision
10. Virginia Tech Coal and Energy Center selected for study of CO2 injection into storage reservoirs
11. Large human study links phthalates, BPA and thyroid hormone levels
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study uses new stem cell therapy in patients up to 19 days after stroke
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading ... the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio ... and clinical trial team. , Using the CONSULT module, patients and physicians can schedule ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology: